Pooled analysis assessing the efficacy and safety of amphetamine derivative adjunctive therapy for bipolar depression
Journal of Affective Disorders · 2026-12 · 414 · 122257
DOI: 10.1016/j.jad.2026.122257 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026-12. Verfasst von Mark A Frye und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA. Electronic address: mfrye@mayo.edu. Hauptthemen laut MEDLINE: Bipolar Disorder, Central Nervous System Stimulants, Amphetamine, Dextroamphetamine. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Individualized Medicine, Mayo Clinic, J Willard and Alice S Marriott Foundation.
Themen: Depression
Abstract (Originalsprache)
OBJECTIVE: The bipolar pharmacopoeia targeting depression is significantly underdeveloped. Despite high rates of attention deficit symptoms, there has been inadequate investigation of stimulants as a treatment intervention for adults with bipolar depression. METHODS: Data were pooled from two, 8-week, randomized, placebo-controlled trials of adjunctive mixed d-amphetamine/l-amphetamine salt (MAS) and lisdexamfetamine (LDX). The primary outcome measure was baseline-to-endpoint change in the Montgomery-Asberg Depression Rating Scale (MADRS). Secondary outcomes included treatment response and remission (50%MADRS reduction, MADRS < 10), and improvement as measured by the Clinical Global Impression for Bipolar Disorder (CGI-BP). The primary safety assessment was the Young Mania Rating Scale (YMRS). RESULTS: Fifty-seven bipolar [BD-I: n = 23 (40.4%); BD-II: n = 34 (59.6%); male: n = 17 (29.8%); female: n = 40 (70.2%); mean age = 40.1 ± 11.3 years] depressed participants were randomized. There were no significant group differences in baseline demographics (all p ≥ 0.14). In age-adjusted analysis, participants receiving adjunctive LDX/MAS (n = 26) in comparison to placebo (n = 31) showed greater improvement in MADRS (mean % reduction: 54.6% vs. 25.6%; 95% CI: 9.1, 48.9; p = 0.005), with higher response (65.7% vs. 16.7%; p < 0.001), remission (48.8 vs. 15.3%; p = 0.007) and CGI-BP improvement rates (65.0% vs. 23.5%; p = 0.001). There was no between-group difference in YMRS scores at baseline or endpoint (p ≥ 0.36). CONCLUSIONS: In this pooled controlled analysis, 8-week adjunctive amphetamine was associated with reduction in depressive symptoms in carefully selected patients with bipolar depression, with no increased risk of treatment-emergent mania/hypomania. Further studies are encouraged to identify clinical correlates of treatment response guiding clinicians when to consider this potentially effective treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA. Electronic address: mfrye@mayo.edu.
- Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.
- Department of Psychiatry, University of Utah, Salt Lake City, UT, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
- Lindner Center of HOPE/Department of Psychiatry and Behavioral Neurosciences, University of Cincinnati College of Medicine, Mason, OH, USA.
- Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Förderung
- Center for Individualized Medicine, Mayo Clinic
- J Willard and Alice S Marriott Foundation
Zitieren
APA
Frye, M. A., Sanchez-Ruiz, J. A., Ali, D. N., Nunez, N., Lindstrom, K., Pazdernik, V. K., Mori, N., Singh, B., Cuellar-Barboza, A. B., Georgiev, G., Veldic, M., Ozerdem, A., Biernacka, J. M., & McElroy, S. L. (2026). Pooled analysis assessing the efficacy and safety of amphetamine derivative adjunctive therapy for bipolar depression. Journal of Affective Disorders, 414, 122257. https://doi.org/10.1016/j.jad.2026.122257
Vancouver
Frye MA, Sanchez-Ruiz JA, Ali DN, Nunez N, Lindstrom K, Pazdernik VK, et al. Pooled analysis assessing the efficacy and safety of amphetamine derivative adjunctive therapy for bipolar depression. Journal of Affective Disorders. 2026;414:122257. doi:10.1016/j.jad.2026.122257
BibTeX
@article{Frye2026,
author = {Frye, Mark A and Sanchez-Ruiz, Jorge A and Ali, Dina N and Nunez, Nicolas and Lindstrom, Karin and Pazdernik, Vanessa K and Mori, Nicole and Singh, Balwinder and Cuellar-Barboza, Alfredo B and Georgiev, Georgi and Veldic, Marin and Ozerdem, Aysegul and Biernacka, Joanna M and McElroy, Susan L},
title = {Pooled analysis assessing the efficacy and safety of amphetamine derivative adjunctive therapy for bipolar depression},
journal = {Journal of Affective Disorders},
year = {2026},
volume = {414},
pages = {122257},
doi = {10.1016/j.jad.2026.122257}
}
EUVIMED